We are live on ! Find out more
ACM

ADAR1 Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 340.85%
This Fund
S&P 500
This Quarter Est. Return
+5.02%
1 Year Est. Return
+340.85%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$500M
AUM Growth
-$115M
Cap. Flow
-$85.2M
Cap. Flow %
-17.03%
Top 10 Hldgs %
48.26%
Holding
330
New
47
Increased
56
Reduced
65
Closed
116

Top Buys

Rank Stock Value
1
ZLAB icon
Zai Lab
ZLAB
+$14.3M
2
IKT icon
Inhibikase Therapeutics
IKT
+$12.7M
3
BIL icon
State Street SPDR Bloomberg 1-3 Month T-Bill ETF
BIL
+$10.1M
4
ABVX
Abivax
ABVX
+$9.13M
5
RVMD icon
Revolution Medicines
RVMD
+$6.34M

Top Sells

Rank Stock Value
1
RPRX icon
Royalty Pharma
RPRX
+$27.8M
2
CYTK icon
Cytokinetics
CYTK
+$25.8M
3
KROS icon
Keros Therapeutics
KROS
+$21.9M
4
BBIO icon
BridgeBio Pharma
BBIO
+$19.9M
5
ASND icon
Ascendis Pharma A/S
ASND
+$11.8M

Sector Composition

Rank Sector Weight
1 Healthcare 77.69%
2 Financials 3.07%
3 Communication Services 1.32%
4 Technology 0.33%
5 Consumer Staples 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INZY
151
DELISTED
Inozyme Pharma
INZY
$211K 0.04%
+76,299
New +$290K
NRIX icon
152
Nurix Therapeutics
NRIX
$2.62B
$207K 0.04%
+11,000
New +$252K
LUNG icon
153
Pulmonx
LUNG
$88M
$192K 0.04%
+28,221
New +$186K
DNA icon
154
Ginkgo Bioworks
DNA
$555M
$183K 0.04%
+18,680
New +$160K
AQN icon
155
Algonquin Power & Utilities
AQN
$4.43B
$178K 0.04%
40,000
-40,000
-50% -$193K
QURE icon
156
uniQure
QURE
$3.15B
$177K 0.04%
+10,000
New +$86.3K
CLRB icon
157
Cellectar Biosciences
CLRB
$20.1M
$175K 0.04%
19,509
-14,563
-43% -$673K
AVXL icon
158
Anavex Life Sciences
AVXL
$304M
$174K 0.03%
+16,221
New +$125K
DFTX
159
Definium Therapeutics
DFTX
$6.12B
$174K 0.03%
+25,000
New +$172K
SPRB
160
Spruce Biosciences
SPRB
$128M
$170K 0.03%
5,383
– –
ABOS icon
161
Acumen Pharmaceuticals
ABOS
$165M
$162K 0.03%
+94,294
New +$227K
ARDX icon
162
Ardelyx
ARDX
$1.2B
$157K 0.03%
31,035
+24,635
+385% +$136K
BKHA
163
Black Hawk Acquisition Corp
BKHA
$156K 0.03%
15,000
– –
PMVP icon
164
PMV Pharmaceuticals
PMVP
$62.9M
$153K 0.03%
101,008
– –
CTMX icon
165
CytomX Therapeutics
CTMX
$734M
$149K 0.03%
145,036
-758,923
-84% -$816K
RGNX icon
166
CALL
Regenxbio
RGNX
$745M
$138K 0.03%
17,800
– –
ATAI icon
167
AtaiBeckley Inc
ATAI
$2.66B
$133K 0.03%
+100,000
New +$133K
CASI
168
DELISTED
CASI Pharmaceuticals
CASI
$131K 0.03%
46,320
-18,515
-29% -$87.8K
BOLT icon
169
Bolt Biotherapeutics
BOLT
$7.44M
$131K 0.03%
12,248
– –
SLN
170
Silence Therapeutics
SLN
$554M
$124K 0.02%
18,000
-22,290
-55% -$288K
OVID icon
171
Ovid Therapeutics
OVID
$495M
$122K 0.02%
130,532
+92,789
+246% +$104K
IOVA icon
172
Iovance Biotherapeutics
IOVA
$2.77B
$116K 0.02%
15,700
– –
AMPY icon
173
Amplify Energy
AMPY
$168M
$111K 0.02%
18,475
– –
LYRA
174
DELISTED
LYRA THERAPEUTICS INC
LYRA
$110K 0.02%
+10,664
New +$117K
SAGE
175
DELISTED
Sage Therapeutics
SAGE
$104K 0.02%
19,200
-32,450
-63% -$198K
5 6
7
8 9

Similar funds

RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return

ADAR1 Capital Management's Q4 2024 Portfolio in Review

As of Q4 2024, ADAR1 Capital Management held 330 positions worth $500M, down 19% from $615M the previous quarter. Its ten largest holdings account for 48% of the portfolio.

ADAR1 Capital Management withdrew a net $85.2M in Q4 2024, closing 116 positions and reducing 65 holdings. Its most notable exit was Syndax Pharmaceuticals, an estimated $6.74M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 78% of assets, down from 86% a quarter earlier, followed by Financials and Communication Services.

Against the trend, ADAR1 Capital Management opened a new position in Inhibikase Therapeutics worth $16.6M.

  • ADAR1 Capital Management's largest Q4 2024 buy was Inhibikase Therapeutics: 5,103,005 shares worth $16.6M.
  • ADAR1 Capital Management added most to Zai Lab in Q4 2024, an estimated $14.3M increase.
  • ADAR1 Capital Management's biggest Q4 2024 reduction was Royalty Pharma, cutting an estimated $27.8M.
  • ADAR1 Capital Management fully exited Syndax Pharmaceuticals in Q4 2024, selling an estimated $6.74M.
  • ADAR1 Capital Management's ten largest holdings make up 48% of its $500M portfolio in Q4 2024.
  • ADAR1 Capital Management opened 47 new positions and closed 116 in Q4 2024.
  • ADAR1 Capital Management's portfolio value fell 19% quarter-over-quarter to $500M.

Based on ADAR1 Capital Management's 13F filing for Q4 2024, filed 13 Feb 2025.